Articles from Curia Global, Inc.

ALBANY, N.Y., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), a leading contract research, development and manufacturing organization, today announced its Burlington, MA sterile drug product facility has been named “Manufacturer of the Year” by the Massachusetts Legislative Manufacturing Caucus. The award was presented at the 10th Annual Manufacturing Awards Ceremony, held on Oct. 21 at Gillette Stadium.

ALBANY, N.Y., March 17, 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), a leading contract research, development and manufacturing organization, today announced expansion plans to its Glasgow, UK facility and provided updates on the ongoing expansion in Albuquerque, NM.

ALBANY, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), a leading contract research, development and manufacturing organization, today announced it has refinanced its senior secured credit facilities.

ALBANY, N.Y., Oct. 08, 2024 (GLOBE NEWSWIRE) --  Curia, a leading contract research, development and manufacturing organization, today announced its commitment to set near- and long-term company-wide greenhouse gas (GHG) emission reductions in line with science-based net-zero with the Science Based Targets initiative (SBTi). To achieve this goal, Curia will be investing resources over the next two years to evaluate and develop GHG emission reduction targets for submission to and approval by the SBTi.

The refined brand highlights Curia’s key capabilities and personalized approach across small molecules, generic APIs and biologics

ALBANY, N.Y. and SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization and Carterra Inc., the world leader in label-free high throughput antibody and small molecule drug discovery, today announced their partnership in hosting a high-throughput biologics symposium slated for May 31 at the Residence Inn at Marriott in Seattle, Washington.

Curia recognized for its Service in the CDMO industry

ALBANY, N.Y., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, today announced that Gerald Auer has been appointed as chief financial officer. He will join the organization effective Jan. 1, 2024.

ALBANY, N.Y., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, today announced it has been recognized as one of the top 10 CDMOs in India by India Pharma Outlook. The full list can be viewed in the November 2023 edition of the India Pharma Outlook magazine.

Supply of drug substance manufactured under cGMP supports first-in-human clinical study for RBI-4000 novel self-replicating RNA (srRNA)

Curia collaborates with Touchlight to expand its mRNA manufacturing offering to enable access to enzymatic doggybone DNA (dbDNA™)

Curia recognized for providing a best-in-class customer experience in the CRDMO industry through its innovative approach and growth strategy

Curia signs license agreement with MilliporeSigma to support production of proteins and antibodies

Collaboration marks the first global installation of Corning’s G1 production system to support higher-quality API-chemical production using inherently safer flow-chemistry technology

ALBANY, N.Y., March 16, 2023 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, today announced that Philip Macnabb has been appointed as chief executive officer, succeeding John Ratliff.